Detailed Information

Cited 70 time in webofscience Cited 70 time in scopus
Metadata Downloads

Recent research trends and updates on nonalcoholic fatty liver disease

Full metadata record
DC Field Value Language
dc.contributor.authorYoo, Jeong-Ju-
dc.contributor.authorKim, Won-
dc.contributor.authorKim, Moon Young-
dc.contributor.authorJun, Dae Won-
dc.contributor.authorKim, Sang Gyune-
dc.contributor.authorYeon, Jong-Eun-
dc.contributor.authorLee, Jin Woo-
dc.contributor.authorCho, Yong Kyun-
dc.contributor.authorPark, Sang Hoon-
dc.contributor.authorSohn, Joo Hyun-
dc.date.available2020-11-02T06:41:21Z-
dc.date.issued2019-03-
dc.identifier.issn2287-2728-
dc.identifier.issn2287-285X-
dc.identifier.urihttps://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2337-
dc.description.abstractNonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of endstage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.-
dc.format.extent11-
dc.language영어-
dc.language.isoENG-
dc.publisher대한간학회-
dc.titleRecent research trends and updates on nonalcoholic fatty liver disease-
dc.typeArticle-
dc.publisher.location대한민국-
dc.identifier.doi10.3350/cmh.2018.0037-
dc.identifier.scopusid2-s2.0-85057764482-
dc.identifier.wosid000461751500001-
dc.identifier.bibliographicCitationClinical and Molecular Hepatology, v.25, no.1, pp 1 - 11-
dc.citation.titleClinical and Molecular Hepatology-
dc.citation.volume25-
dc.citation.number1-
dc.citation.startPage1-
dc.citation.endPage11-
dc.type.docTypeReview-
dc.identifier.kciidART002446955-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClassesci-
dc.description.journalRegisteredClasskci-
dc.relation.journalResearchAreaGastroenterology & Hepatology-
dc.relation.journalWebOfScienceCategoryGastroenterology & Hepatology-
dc.subject.keywordPlusHOMEOSTASIS MODEL ASSESSMENT-
dc.subject.keywordPlusHEPATOCELLULAR-CARCINOMA-
dc.subject.keywordPlusHISTOLOGICAL SEVERITY-
dc.subject.keywordPlusSTIFFNESS MEASUREMENT-
dc.subject.keywordPlusNATURAL-HISTORY-
dc.subject.keywordPlusNONINVASIVE ASSESSMENT-
dc.subject.keywordPlusAMERICAN ASSOCIATION-
dc.subject.keywordPlusNONOBESE PATIENTS-
dc.subject.keywordPlusINCREASED RISK-
dc.subject.keywordPlusSTEATOHEPATITIS-
dc.subject.keywordAuthorNonalcoholic fatty liver disease-
dc.subject.keywordAuthorNonalcoholic steatohepatitis-
dc.subject.keywordAuthorClinical trial-
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yeon, Jong Eun photo

Yeon, Jong Eun
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE